4.1 Ischemia–Reperfusion Injury

Ischemia–Reperfusion Injury in Liver Transplantation

Comprehensive Summary | Module 4.1 | Prof. Sanjaya Satapathy, MD, FAASLD

1. Main Clinical Topics Discussed

• Pathophysiology of ischemia–reperfusion injury (IRI) in liver transplantation
• Expected laboratory patterns and clinical timeline post-transplant
• Differentiation of IRI from Early Allograft Dysfunction (EAD) and Primary Non-Function (PNF)
• Risk stratification and red flags requiring urgent evaluation
• Supportive management principles

2. Key Learning Points, Guidelines, and Recommendations

Definition and Significance

• IRI is universal after liver transplantation; every graft experiences some degree of ischemic insult followed by reperfusion injury
• Mild-to-moderate transaminase elevation in the first 24–72 hours is expected and physiologically normal
• IRI represents the primary physiologic basis of Early Allograft Dysfunction (EAD)

Pathophysiology (Sequential Cascade)

1. Ischemia → ATP depletion: Oxidative phosphorylation ceases; Na⁺/K⁺ pump failure → cellular swelling and calcium influx

2. Mitochondrial dysfunction: Organelles become unstable and primed for reperfusion injury

3. Reperfusion → Reactive Oxygen Species (ROS) burst: Lipid peroxidation, protein damage, DNA injury, membrane disruption

4. Kupffer cell activation: Resident macrophages detect DAMPs and amplify the inflammatory response

5. Cytokine release (TNF-α, IL-1, IL-6): Neutrophil recruitment, worsening microvascular injury

6. End result: Hepatocellular injury and sinusoidal endothelial damage

> Key concept: *"Ischemia sets the stage; reperfusion pulls the trigger."*

Cold vs. Warm Ischemia Time

• Cold Ischemia Time (CIT): From cross-clamp in donor to implantation start; metabolism slows but cellular injury progresses
• Warm Ischemia Time (WIT): During implantation at body temperature without perfusion; especially critical in DCD donors who have an additional functional warm ischemia period prior to procurement
• Longer ischemia time (cold or warm) = higher risk of severe IRI and EAD

3. Specific Clinical Data, Statistics, and Study Results Cited

Expected Laboratory Values and Timeline

• Typical IRI range: AST/ALT 1,000–3,000 U/L
• Severe IRI (prolonged CIT, DCD, marginal donors): AST/ALT may exceed 5,000 U/L
• Bilirubin: typically normal initially (cholestasis takes time to develop)
• Lactate: may transiently rise at reperfusion but should clear
• INR: mild transient elevation expected; progressive worsening is pathological

> Key teaching point: An AST of 4,000–6,000 U/L does not define PNF if the value peaks early and declines. Magnitude alone does not equal graft failure.

IRI vs. Primary Non-Function (PNF) — Distinguishing Features

IRI vs. Acute Cellular Rejection (ACR)

• **I